股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 蘇州旺山旺水生物醫藥股份有限公司（「本公司」） 呈交日期: 2026年1月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02630 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 66,677,133 | RMB | | 1 | RMB | | 66,677,133 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 66,677,133 | RMB | | 1 | RMB | | 66,677,133 | | 2. 股 ...

Vigonvita Life Sciences Co., Ltd. 蘇州旺山旺水生物醫藥股份有限公司 (a joint stock company incorporated in the People's Republic of China with limited liability) （於中華人民共和國註冊成立的股份有限公司） (Stock Code 股份代號: 2630) 22 December 2025 Dear non-registered shareholder(s), 各位非登記股東： Pursuant to Rule 2.07A of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") under the expansion of paperless listing regime and electronic dissemination of corporate communications that came into ef ...

Vigonvita Life Sciences Co., Ltd. 蘇州旺山旺水生物醫藥股份有限公司 (a joint stock company incorporated in the People's Republic of China with limited liability) （於中華人民共和國註冊成立的股份有限公司） (Stock Code 股份代號: 2630) Dear registered shareholder(s), 22 December 2025 Arrangement of Electronic Dissemination of Corporate Communications Pursuant to Rule 2.07A of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") under the expansion of paperless listing regime and electronic diss ...

每经AI快讯，旺山旺水-B(02630.HK)午后拉升逾15%，截至发稿涨14.81%，报88港元，成交额1333.12 万港元。 ...

Core Viewpoint - The stock of 旺山旺水-B (02630) surged over 15% in the afternoon, reaching a price of 88 HKD, with a trading volume of 13.33 million HKD, following the announcement of a licensing agreement with 先声药业 for the new indication of VV116 [1] Group 1: Licensing Agreement - 旺山旺水 has entered into a licensing agreement with 先声药业, granting the latter exclusive rights to the use of hydrogen bromide dextromethorphan suspension for treating respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) infections in the Greater China region [1] - This collaboration aims to leverage the strengths of both companies in research, production, and commercialization to accelerate the clinical development and commercialization of VV116, ultimately benefiting more patients [1] Group 2: Company Pipeline and Focus Areas - 旺山旺水 is focused on three main therapeutic areas: neuropsychiatry, reproductive health, and viral infections [1] - As of October 21, 2025, the company has established a diversified pipeline of nine innovative products, with two in the commercialization stage, four in clinical stages, and three in preclinical stages [1] - In addition to its innovative drug pipeline, 旺山旺水 is also involved in the generic drug sector, with three products either commercialized or nearing commercialization [1] - The company's two core products are LV232 and TPN171 [1]

Core Viewpoint - The stock of Wangshan Wangshui-B (02630) surged over 15% following the announcement of a licensing agreement with Sihuan Pharmaceutical for the new indication of VV116, aimed at treating RSV and HMPV infections in Greater China [1] Group 1: Company Developments - Wangshan Wangshui has entered into a licensing agreement with Sihuan Pharmaceutical, granting exclusive rights for the use of dextromethorphan hydrobromide in treating RSV and HMPV infections in Greater China [1] - The collaboration aims to leverage the strengths of both companies in research, production, and commercialization to accelerate the clinical development and commercialization of VV116 [1] Group 2: Product Pipeline - As of October 21, 2025, Wangshan Wangshui has established a diversified pipeline of 9 innovative products, with 2 in the commercialization stage, 4 in clinical stages, and 3 in preclinical stages [1] - The company also has a generic drug segment, with 3 products either commercialized or nearing commercialization [1] - The two core products of Wangshan Wangshui are LV232 and TPN171 [1]

Core Viewpoint - The extreme drop in the stock price of Wangshan Wangshui-B (02630) from HKD 97 to HKD 51, a nearly 50% decline, is seen as a recalibration of market order rather than the end of the story, leading to a clear double W bottom formation and subsequent upward trend [1] Phase 1: Panic Sell-off and Liquidity Crisis - From November 6 to November 12, the newly listed Wangshan Wangshui experienced a rapid decline of 44.37%, dropping from HKD 97 to HKD 51, which is still approximately 70% above the issue price of HKD 33.37, indicating that the drop was more about eliminating irrational early-stage bubbles [2] - The total trading volume during this period was 7.8622 million shares, with a 94.9% bearish volume ratio, suggesting that almost all liquid shares underwent a turnover, providing a solid foundation for new institutional investors [2][3] Phase 2: Double W Bottom Formation and Shift in Market Sentiment - From November 13 to November 21, the market quickly organized a rebound, forming a right bottom at HKD 52.55, which is higher than the left bottom at HKD 51, confirming the area as an effective low point [4] - The bullish volume reached 974,200 shares, surpassing the bearish volume of 846,400 shares for the first time since the drop, indicating a fundamental shift in market sentiment [4] Phase 3: Main Uptrend Breakthrough and Self-Reinforcing Trend - From November 24 to December 2, the stock price surged from HKD 59.85 to HKD 79.3, a 31.42% increase, successfully breaking through the neck line at HKD 74, indicating a strong bullish trend [6] - The low turnover rate of 1.13% during this period suggests that circulating shares were highly locked, indicating strong control by the main force [6] Phase 4: Healthy Consolidation and Technical Confirmation Post Main Uptrend - From December 3 to December 11, the stock price corrected from a high of HKD 79.3 to a low of HKD 70.5, resulting in a 7.80% decline, which is considered a healthy adjustment rather than a trend reversal [8] - The total trading volume of 962,440 shares during this period was slightly higher than during the main uptrend, indicating a typical "pullback with volume" phenomenon, while the 1.44% turnover rate suggests good locking of shares despite the adjustment [10][11]

在资本市场的技术分析框架中，一次极端的"断崖式"暴跌，往往并非故事的终点，而可能是一场精密计 算的秩序重构。 智通财经APP观察到，旺山旺水-B（02630）在经历从97元至51元、幅度近50%的垂直打击后，并未陷 入漫长的阴跌，反而在迅速构筑起一个结构清晰、量价配合经典的双W底形，并最终展开一轮流畅的主 升浪。下文，我们将穿透K线图与成交量的表层，剖析其背后主力运作的深层逻辑与市场情绪转换的微 观密码。 第一阶段：恐慌性暴跌与流动性危机 11月6日至12日，刚刚上市的旺山旺水经历了一场极限压力测试。其股价在短短5个交易日内从97港元的 高点急速坠落至51港元，累计跌幅达44.37%，完成了次近乎腰斩的极端调整。 值得关注的是，即使跌至51元低点，股价仍比发行价33.37港元高出约70%。这表明暴跌并未跌破发行 价这一核心价值锚，更多是挤出上市初期非理性泡沫的过程。此外，当首批获利丰厚的筹码（以发行价 计获利仍超70%）开始集体兑现时，由于流通盘（仅十分之一股份）本身很小，巨大的卖盘相对于有限 的活跃买盘形成碾压。 786.22万手的区间总成交与94.9%的阴量占比，以及超过10%的换手，意味着几乎所有流动筹 ...

Core Viewpoint - The licensing agreement between Xiansheng Pharmaceutical and Wangshan Wangshui for dextromethorphan hydrobromide is a significant development, as it positions Xiansheng to potentially launch the world's first nucleoside-based drug for RSV infections in Greater China [1] Group 1: Licensing Agreement - Xiansheng Pharmaceutical has entered into a licensing agreement with Wangshan Wangshui for dextromethorphan hydrobromide [1] - The agreement grants Xiansheng exclusive rights to the drug in Greater China for treating respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) infections [1] Group 2: Drug Approval Status - Dextromethorphan hydrobromide tablets have already received regular approval in China for treating mild to moderate COVID-19 infections in adults [1] - The drug is expected to become the first approved nucleoside-based treatment for RSV globally [1]

Core Viewpoint - The announcement indicates that the stabilization period for the global offering of 旺山旺水-B (02630) has ended as of December 3, 2025, with no excess allocation of H-shares during the international offering [1] Group 1 - The stabilization period concluded on December 3, 2025, which is 30 days after the deadline for submitting the Hong Kong public offering application [1] - There were no stabilization actions taken by the stabilizing agent or any person acting on its behalf during the stabilization period [1] - The sponsor and overall coordinator did not exercise the over-allotment option, which has now lapsed as of December 3, 2025 [1]